Vitamin K — IM Shot, Oral, or Decline — Evidence Library

What it is

Babies are born with very low vitamin K, and until ~6 months of solid food they can't reliably make it. Without supplementation, roughly 1 in 14,000 babies develops Vitamin K Deficiency Bleeding (VKDB) — including a late form (weeks 2–24) that often presents as brain bleeding with a ~20% death rate. The standard IM shot at birth prevents virtually all cases. Oral protocols (used in several European countries) require multiple doses over weeks and reduce but don't eliminate late VKDB, especially in exclusively breastfed babies. In the US, all major pediatric societies recommend IM; oral is not FDA-approved and no standardized oral product exists.

Evidence review links

Each link opens the full review on the publisher's site in a new tab.

Possible benefits

IM shot: single dose, one-and-done, near-100% protection for the whole vulnerable windowReview sources ↓
Oral protocol (where available and followed): needle-free, effective if all doses are given on scheduleReview sources ↓
Both dramatically reduce the risk of catastrophic late brain bleedingReview sources ↓

Possible risks

IM: brief pain, small bruise; extremely rare local reactionReview sources ↓
Oral: missed doses = much higher failure rate; exclusively breastfed babies at higher risk of failure even with adherenceReview sources ↓
Declining entirely: about 1 in 14,000 risk of VKDB, and the late form can be fatal or cause permanent disabilityReview sources ↓
A widely-cited 1990s study suggesting a leukemia link has been repeatedly disprovenReview sources ↓

Alternatives

IM shot at birth (standard in the US and most of the world)Review sources ↓
Oral multi-dose protocol where available, with explicit follow-through planReview sources ↓
Give with skin-to-skin, breastfeeding, or sucrose to reduce discomfortReview sources ↓
Delay by 1–6 hours to allow uninterrupted golden hour if baby is stableReview sources ↓

Current evidence

AAP restated its IM recommendation in 2022; the CDC, WHO, and NICE all recommend prophylaxis with a preference for IM. Multiple studies (including the pooled UK Childhood Cancer Study) found no leukemia link. Dutch and Danish surveillance data show that oral protocols reduce but don't eliminate late VKDB, particularly with cholestatic liver disease that may be silent at birth.

Where the evidence is clear · where people may choose differently

For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.

Educational only. Your care team can help you weigh what applies to your specific situation.